Search for dialysis centres here

Find a centre Log in to explore the world's most comprehensive database of dialysis centres for free!

Jobs in dialysis

dialysis.team.logo.small.000 Professional dialysis recruitment 

 

Dialysis industry news

Stories from the dialysis comunity across the globe.
NxStage Celebrates Second Annual National Home Hemodialysis Day - CNNMoney PDF Print

LAWRENCE, Mass., March 19, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, is proud to celebrate the second annual Home Hemodialysis Day today, March 19, 2015, during National Kidney Month. Observed annually on the third Thursday of March, this initiative is dedicated to raising awareness of home hemodialysis, including nocturnal therapy, with the NxStage® System One? and empowering dialysis patients to choose a therapy that is right for them. This evening in Boston, the city's iconic Zakim Bridge will be lit green in support of NxStage's awareness efforts and to commemorate Home Hemodialysis Day.

NxStage Medical, Inc.

Home Hemodialysis Day provides a platform for home dialyzors and their care partners to share their experiences and stories with others to strengthen the home hemodialysis community.  To celebrate the day, NxStage is distributing green ribbons at dialysis centers across the country and highlighting inspiring patient stories at http://ww2.nxstage.com/patient-stories.html.  At the same time, the Company is encouraging patients and care partners to unite, spread the word and capture their support using the hashtag, #HomeHemodialysisDay. 

"With home nocturnal therapy, I get to live life on my own terms," said Robby Richardson of Savannah, GA who performs more frequent nocturnal therapy at home with the System One. "By doing my treatments while I sleep, I feel better and am able to maintain my full-time job teaching special education to high school students. Nocturnal therapy has worked so well for me that I've also gone back to my passion of leading ghost tours around the historic district in Savannah. Nocturnal therapy has allowed me to make dialysis work for my life, and not the other way around."

"We have made huge strides in advancing access to home hemodialysis care over the years, most recently receiving FDA clearance for the System One as the first and only machine approved for nocturnal therapy," said NxStage President, Joe Turk. "Still, only a tiny fraction of patients that could truly benefit have access today.  We are building on the tradition of National Home Hemodialysis Day to empower all of our patients to share their life-changing stories, and help others understand the significant clinical and quality of life benefits that our home hemodialysis therapies can offer."

For more information about the System One, or home nocturnal hemodialysis, please visit www.nxstage.com. To see Robby Richardson's personal account of his experience with home hemodialysis, please visit our YouTube page.

Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.

Additional Risks Associated with Nocturnal Home Hemodialysis Therapy
The NxStage System One may be used at night while the patient and care partner are sleeping. Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep. Ancillary anticoagulant infusion pumps and fluid leak detection devices may be used to decrease certain risks for home hemodialysis treatments performed at any time, but NxStage requires the use of fluid leak detectors to identify leaks from the vascular access, Cycler and Cartridge when performing nocturnal therapy with the NxStage System One.

About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.

About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact: 
Kristen K. Sheppard, Esq.
ksheppard@nxstage
Tel: (978) 332-5923

Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-celebrates-second-annual-national-home-hemodialysis-day-300052789.html

SOURCE NxStage Medical Inc.

 Top of page

...
 
ProMetic Successfully Completes Its PBI-4050 Phase Ib in Patients With Chronic ... - Marketwired (press release) PDF Print

LAVAL, QUEBEC--(Marketwired - March 19, 2015) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") reported today that it has successfully completed its PBI-4050 Phase Ib multi-dose clinical trial in patients with chronic kidney disease. ProMetic's orally active lead drug candidate, PBI-4050, was found to be safe and well tolerated without any serious adverse events reported.

The objectives of this, randomized, double-blind, placebo-controlled, multi-dose study were to demonstrate the safety and tolerability of PBI-4050 and to determine the pharmacokinetic profile of PBI-4050 following multiple oral doses over 10 days in patients with stage 3b or 4 stable renal impairment. The trial was conducted in 8 patients with 6 patients receiving PBI-4050 and 2 patients receiving matching placebo.

"We are pleased to see that the safety and pharmacokinetic profiles of our lead drug candidate remain unaffected by the severely impaired renal function in the patients tested", commented Dr. John Moran, ProMetic's Chief Medical Officer. "Since fibrosis is the pathological pathway leading to organ failure and death in many diseases of differing aetiologies and affecting various organs, we plan to test the efficacy of this drug in several of fibrosis-related conditions"

The Phase II clinical trial in patients suffering from the metabolic syndrome and the resulting Type 2 diabetes is scheduled for patient enrolment to commence in April, 2015 following the recent CTA clearance by Health Canada. PBI-4050 has also received an orphan drug designation status by the FDA for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") and a phase II trial in IPF has been cleared by Health Canada and is scheduled to commence in the coming weeks.

Both phase II trials are 12 weeks, open-label, single-arm, exploratory Phase II studies to evaluate the safety and tolerability of PBI-4050 in 40 patients suffering from IPF and 12 to 36 patients suffering from the metabolic syndrome and the resulting type 2 diabetes. Both Phase II trials will gather data on the effects of PBI-4050 and will monitor each patient's progress against their own respective baseline.

Following the confirmation of PBI-4050's safety profile in both healthy volunteers and patients, the Corporation is expanding its clinical programs in both the US and EU in existing indications and in rare disease indications associated with fibrosis.

More on PBI-4050

PBI-4050 is an orally active lead drug candidate with excellent efficacy and safety profiles confirmed in several in vivo experiments targeting fibrosis. Fibrosis is a very complex process by which continuing inflammation causes vital organs to lose their function as normal tissue is gradually replaced by fibrotic scar tissue. The proof of concept data generated to date confirms our lead drug candidates' anti-fibrotic activity in several key organs including the kidneys, the heart, the lungs and the liver. Twenty six million patients in the U.S. alone are diagnosed with chronic kidney diseases ("CKD"). Patients with severe CKD stages (3 and 4) suffer from a gradual and accelerated loss of their renal function (end stage renal disease or ESRD) leading to the need for maintenance dialysis or kidney transplant.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.

Forward-Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in ProMetic's Annual Information Form for the year ended December 31, 2013, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

...
 
Dialysis patients triple in a decade - Royal Gazette PDF Print
Royal Gazette
The number of patients receiving dialysis treatment at King Edward VII Memorial Hospital has risen by 207 per cent in a little more than decade — and is expected to increase further. The facility is treating 166 patients, compared with 54 patients in

...
 
Social Secuity helps people with kidney disease - TriCities.com PDF Print

Posted: Wednesday, March 18, 2015 10:49 am | Updated: 12:08 am, Thu Mar 19, 2015.

Social Secuity helps people with kidney disease Trevor Drozdowski TriCities.com

Every March, we pay special attention to the kidney, an organ vital to a healthy life. Social Security wants to help spread the word about the importance of kidney health and about what you should do if you think you or a loved one has a kidney-related disability.

Kidney disease prevents your kidneys from cleansing your blood to their full potential. Did you know that one out of three Americans is currently at high risk for developing kidney disease? According to the Centers for Disease Control and Prevention, 20 million Americans have chronic kidney disease, and most of them don’t even know it.

Subscription Required

An online service is needed to view this article in its entirety. You need an online service to view this article in its entirety.

Have an online subscription?

Login Now

Need an online subscription?

Subscribe

Login

Need more information about All Access? Get all of the details here.

If you are a current subscriber and haven’t signed up for All Access yet, get started here.

Choose an online service.

The following services are print only and offer no digital access

You must login to view the full content on this page.

Need more information about All Access? Get all of the details here.

If you are a current subscriber and haven’t signed up for All Access yet, get started here.

kAmt3:6 :D 2 AC:>6 6I2>A=6] t3:6 H2D 2? 6>6C86?4J C@@> H@C<6C H:E9 2? 24E:G6 =:76 2E H@C<[ 9@>6[ 2?5 :? 9:D 4@>>F?:EJ] w6 925 ?@ :562 96’5 56G6=@A65 2 <:5?6J 4@?5:E:@? F?E:= @?6 52J 96 76=E :== H9:=6 5C:G:?8 E@ H@C< 2?5 925 E@ 42== 2 4@H@C<6C 7@C 96=A]k^Am kAm~FC u246D 2?5 u24ED @7 s:D23:=:EJ H63D:E6 762EFC6D t3:6’D DE@CJ] w6 D2JD A6@A=6 H9@ C646:G6 $@4:2= $64FC:EJ 5:D23:=:EJ 36?67:ED “42? AC@G:56 7@C E96>D6=G6D 36EE6C 2?5 92G6 2 9:89 BF2=:EJ @7 =:76]” pD t3:6 6IA=2:?D[ >2?J A6@A=6 H:E9 <:5?6J 5:D62D6D 42? 8C62E=J :?4C62D6 E96:C BF2=:EJ @7 =:76 H:E9 $@4:2= $64FC:EJ 36?67:ED] *@F 42? =62C? >@C6 23@FE t3:6’D DE@CJ 2E k2 9C67lQ9EEAi^^HHH]D@4:2=D64FC:EJ]8@G^5:D23:=:EJ724EDQmHHH]D@4:2=D64FC:EJ]8@G^5:D23:=:EJ724EDk^2m]k^Am kAmx7 2 <:5?6J 5:D62D6 DF49 2D 6?5\DE286 C6?2= 5:D62D6 W<?@H? 2D t$#sX C6BF:C6D 49C@?:4 5:2=JD:D 2?5 AC6\G6?ED J@F 7C@> H@C<:?8[ $@4:2= $64FC:EJ >2J 36 23=6 E@ 96=A J@F] x7 J@F’C6 F?56C8@:?8 5:2=JD:D[ 92G6 925 2 <:5?6J EC2?DA=2?E[ 92G6 A6CD:DE6?E =@H 4C62E:?:?6 4=62C2?46 =6G6=D[ @C 92G6 A6CD:DE6?E 9:89 D6CF> 4C62E:?:?6 =6G6=D[ J@F >2J BF2=:7J 7@C 5:D23:=:EJ 2?5^@C |65:42C6 36?67:ED] *@F 42? 7:?5 >@C6 :?7@C>2E:@? 23@FE 6=:8:\3:=:EJ 32D65 @? <:5?6J 5:D62D6 2?5 E96 36?67:ED 2G2:=23=6 E@ J@F 3J C625:?8 @FC AF3=:42E:@?D[ s:D23:=:EJ q6?67:ED 2?5 |65:42C6[ 3@E9 2G2:=23=6 2E k2 9C67lQ9EEAi^^HHH]D@4:2=D64FC:EJ]8@G^AF3DQmHHH]D@4:2=D64FC:EJ]8@G^AF3Dk^2m]k^Am kAm{:DE65 2D @?6 @7 $@4:2= $64FC:EJ’D r@>A2DD:@?2E6 p==@H2?46 4@?5:E:@?D[ <:5?6J 42?46C :D 2?@E96C 4@?5:E:@? E92E >2J BF2=:7J J@F 7@C 5:D23:=:EJ 2?5 |65:42C6 36?67:ED] %96 r@>A2DD:@?2E6 p==@H2?46D AC@8C2> 2DD:DED :? 42D6D H96C6 2 A6CD@?’D >65:42= 4@?5:E:@? :D D@ D6G6C6 :E @3G:@FD=J >66ED $@4:2= $64FC:EJ’D 5:D23:=:EJ DE2?52C5D \ 2==@H:?8 BF:4< AC@46DD:?8 @7 E96 5:D23:=:EJ 2AA=:42E:@? 2?5 A2J>6?E @7 36?67:ED] *@F 42? 7:?5 >@C6 :?7@C>2E:@? 23@FE r@>A2DD:@?2E6 p==@H2?46D 3J G:D:E:?8 @FC H63D:E6 2E k2 9C67lQ9EEAi^^HHH]D@4:2=D64FC:EJ]8@G^4@>A2DD:@?2E62==@H2?46DQmHHH]D@4:2=D64FC:EJ]8@G^4@>A2DD:@?2E62==@H2?46Dk^2m]k^Am kAmsC:?< A=6?EJ @7 H2E6C[ 8@ 7@C 4964<FAD[ 2?5 :7 J@F E9:?< J@F >2J 92G6 2 <:5?6J 5:D62D6[ E2<6 24E:@? C:89E 2H2JP pD t3:6 D2JD[ “BF2=:EJ @7 =:76 :D 6G6CJE9:?8]”k^Am kAmx7 J@F E9:?< J@F >2J 36 6=:8:3=6 7@C $@4:2= $64FC:EJ 5:D23:=:EJ 36?67:ED 32D65 @? 2 <:5?6J 5:D62D6[ A=62D6 5@?’E H2:E] v@ E@ k2 9C67lQ9EEAi^^HHH]D@4:2=D64FC:EJ]8@G^5:D23:=:EJDD:QmHHH]D@4:2=D64FC:EJ]8@G^5:D23:=:EJDD:k^2m[ H96C6 J@F 42? 2AA=J 7@C 36?67:ED @?=:?6]k^Am kAm%C6G@C sC@K5@HD<:[ $@4:2= $64FC:EJ p5>:?:DEC2E:@? 5:DEC:4E >2?286C :D E96 =@42= 4@?E24E] w6 >2J 36 C624965 3J >2:= 2E acgc {66 wHJ][ qC:DE@= 'p aca_`[ 3J A9@?6 gee\d_c\d_`b[ @C 6>2:= k2 9C67lQ>2:=E@i762EFC6Do3C:DE@=?6HD]4@>Qm762EFC6Do3C:DE@=?6HD]4@>k^2m] ':D:E k2 9C67lQ9EEAi^^HHH]D@4:2=D64FC:EJ]8@GQmHHH]D@4:2=D64FC:EJ]8@Gk^2m]k^Am

© 2015 TriCities.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Thank you for reading 12 free articles on our site. You can come back at the end of your 30-day period for another 12 free articles, or you can purchase a subscription and continue to enjoy valuable local news and information. If you need help, please contact our office at 276-669-2181. You need an online service to view this article in its entirety.

Have an online subscription?

Login Now

Need an online subscription?

Subscribe

Login

Need more information about All Access? Get all of the details here.

If you are a current subscriber and haven’t signed up for All Access yet, get started here.

Choose an online service.

The following services are print only and offer no digital access

Posted in on Wednesday, March 18, 2015 10:49 am. Updated: 12:08 am.

...
 
Kidney disease awareness grows as new dialysis cases drop - Arizona Daily Sun PDF Print

World Kidney Day was celebrated recently, and Cheryl Biggs took the time to go to her church in Larimer, Pa., for a free screening for kidney disease by the National Kidney Foundation for one reason.

“A friend of mine, her older sister was doing dialysis at home and it was hard,” she said. “If there is something that can be found easily early on, then why not?”

While the foundation and others continue to spread awareness with events such as the one at the church, national data show that the drumbeat of advice, combined with advances in treating diabetes and high blood pressure, appear to be having an effect.

Last year, for the first time since it began keeping track in 1988, the federal government reported fewer new cases of people going onto dialysis from 2010 to 2011, the most recent years available. And that was after two years in which the number of new cases did not increase.

In the world of kidney disease, this was monumental news — but it attracted scant attention at the time.

“We’ve been a little sheepish about that data,” said Leslie Spry, a spokesman for the National Kidney Foundation and a nephrologist at an independent dialysis center in Lincoln, Neb.

Initially, he said, the U.S. Renal Data System, which collects and analyzes the statistics, “said it may be a blip; it could have been the result of the economic downturn causing fewer people to seek dialysis.”

“But after three years, now maybe you have to believe this isn’t an aberration,” he said.

Why has that figure started going down?

“Awareness is part of it,” said Richard Marcus, director of the division of nephrology at Allegheny General Hospital. “More primary care physicians are aware of chronic kidney disease and are talking about it with their patients.

“But it’s also because we have just gotten better at taking care of these patients that they never reach dialysis and hopefully never will.”

In particular, he said, that means more effectively managing the two leading causes of kidney disease — diabetes and high blood pressure.

Being on dialysis is a trying, painstaking process that typically requires three days a week, four hours each day, sitting in a chair, hooked up to a dialysis machine that does the work your kidneys cannot.

“It’s miserable, let me tell you,” said Jack Silverstein, president of the Western PA Kidney Support Groups. “I was on it for four years, and four years was too much.”

Being on dialysis means a patient is likely to be on the kidney transplant list. Because so many are on the transplant waiting list — about 101,000 currently — compared with the number of kidney transplants performed — less than 17,000 — about 4,400 people a year die waiting for a transplant.

Silverstein was one of the lucky ones. He had a successful transplant in 2002.

“It’s a pity we can’t get more transplants (done),” said Beth Piraino, a nephrologist and nationally known researcher at the University of Pittsburgh. “Because the real answer to all of this is to do more transplants.”

The decrease in new dialysis patients is all the more remarkable because in prior decades, the number of first-time dialysis patients didn’t just grow, it exploded.

From 1988, when the agency began collecting data, the number of new patients “seemed to be inexorably going up 5 to 10 percent a year,” said Paul Eggers, a senior kidney epidemiologist with the National Institutes of Diabetes and Digestive and Kidney Diseases, who works on the report. “But now we’re at the end of a decade where it began to grow more slowly, then leveled off, and now there is some indication that it might just be going down. This is good news.”

...
 
More Articles...
<< Start < Prev 341 342 343 344 345 346 347 348 349 350 Next > End >>

Page 349 of 4210
Share |

Dialysis travel

Dialysis information

Global Dialysis

Copyright © 2026 Global Dialysis. All Rights Reserved.